[Disclosure] Samsung Biologics (207940) Reports Q3 2024 Revenue of KRW 1.19T, Up 14.8% YoY

Source Fact: Financial Supervisory Service DART / 2024-10-23

Disclosure Type: Earnings Release (Preliminary Results based on Consolidated Financial Statements)

💡 3-Second Summary

Samsung Biologics announced its preliminary Q3 2024 financial results, showcasing steady growth with revenue up 14.81% YoY to KRW 1.19T and operating profit up 6.29% YoY to KRW 338.6B, although its operating profit declined by 22.08% compared to the immediate prior quarter (Q2 2024).

📊 1. [Summary of Core Disclosure & Key Figures]

Preliminary consolidated earnings for Q3 2024. (Label matching verified: Revenue ≥ Operating Profit)

• Q3 2024 Quarter-Specific Performance (Unit: KRW Million)
  • Revenue: 1,187,075 (approx. KRW 1.19T)
    • QoQ: +2.61% / YoY: +14.81%
  • Operating Profit: 338,578 (approx. KRW 338.6B)
    • QoQ: -22.08% / YoY: +6.29%
  • Profit Before Income Tax: 290,999 (approx. KRW 291.0B)
    • QoQ: -37.41% / YoY: -8.00%
  • Net Profit: 264,468 (approx. KRW 264.5B)
    • QoQ: -16.83% / YoY: +10.03%
• Q3 2024 Cumulative Performance (Jan-Sep Total, Unit: KRW Million)
  • Cumulative Revenue: 3,290,883 (approx. KRW 3.29T) | +25.55% vs. prior year cumulative
  • Cumulative Operating Profit: 994,388 (approx. KRW 994.4B) | +30.20% vs. prior year cumulative
  • Cumulative Net Profit: 761,822 (approx. KRW 761.8B) | +34.36% vs. prior year cumulative
• Note: The disclosure does not state specific reasons for the performance fluctuations (such as the YoY increases or the QoQ operating profit decline). These figures are preliminary and subject to change pending an independent external audit.

📈 2. [Expert Insight: Implications for Investors]

• Robust Year-over-Year Growth Trend: The company’s Q3 revenue and operating profit climbed by 14.81% and 6.29% YoY, respectively, driving cumulative 9-month operating profit near the KRW 1.0T milestone (+30.20%). These numbers validate that the company’s mid-to-long-term top-line expansion and core profitability remain on a healthy upward trajectory.
• Sequential Margin Compression: Despite a modest QoQ revenue increase of 2.61% from Q2 2024, operating profit fell sharply by 22.08%, and pre-tax profit dropped 37.41%. While reasons are omitted in the text, seasonal variables—such as localized plant maintenance windows, shift in batch delivery schedules, or currency headwinds—could have exerted a temporary negative impact.
• Investor Consideration: While the structural macro growth remains intact, market participants may focus on the sequential drop in quarterly profitability. Because this filing focuses strictly on macro numbers without detailed operational commentary, investors are highly encouraged to cross-reference subsequent IR webcasts and materials to verify localized margin drivers and upcoming plant utilization guidance.

📝 Editor’s Comment (by K-STOCK Editor)

Samsung Biologics’ Q3 scorecard reflects strong year-over-year operational expansion matched with a short-term sequential consolidation. The fact that cumulative revenue is approaching KRW 3.3T firmly reconfirms its solid macro position in the global biopharma landscape. However, the 22% sequential drop in operating profit compared to Q2 will likely draw close investor inspection. In the commercial CMO arena, quarter-on-quarter variations are highly common, often triggered by specific batch clearing schedules, localized utility maintenance, or uneven raw material pacing. Shareholders should examine the concurrent IR detailed breakdown to determine whether this indicates a structural margin squeeze or simply a routine, non-recurring accounting layout.

📢 Disclaimer & Source Information

Source: This content was structured and newly generated based on official data submitted to the Financial Supervisory Service’s Electronic Disclosure System (DART).

Investment Risk Notice: This information is provided solely for informational and linguistic reference purposes. Under no circumstances does it constitute financial advice or a recommendation to buy or sell specific stocks. All investment decisions and financial liabilities rest entirely with the investor.

Contact: For compliance-related inquiries or copyright requests, please contact ksb220805@gmail.com.